Comparison of the effects of single predonine and predonine-iguratimod therapy on the old elderly onset arthritis.randomized controlled trial. - The effects of iguratimod therapy on the elderly onset arthritis.

开始日期2016-08-01

申办/合作机构-

100 项与氢化泼尼松琥珀酸钠相关的临床结果

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的转化医学

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的专利（医药）

登录后查看更多信息

776

项与氢化泼尼松琥珀酸钠相关的文献（医药）

2024-04-08·Cureus

Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study

Article

作者: Albednah, Fahed A ; Al Harbi, Khalid ; Alkahtani, Abdullah H ; Alammari, Yousef ; Almansour, Mohammed ; Alharbi, Khalid A ; Qutob, Rayan Abubakker ; Alshehry, Hasan Z ; Alsharif, Abdulaziz Y ; Alajaji, Abdulrahman A ; Alrashoudi, Abdulrahman M ; Alsaedi, Ahmed M

BACKGROUNDSystemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition affecting multiple systems. Cardiovascular morbidity is a significant concern, with around 25% of SLE patients experiencing cardiac complications.OBJECTIVEThis study aims to determine the prevalence of cardiovascular morbidity in SLE patients in King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia.METHODOLOGYThis retrospective record-based research was conducted at KFMC from January 2015 to October 2023. A review of the medical files of all SLE patients was accomplished.RESULTSThe vast majority of the patients (90.9%) were females. The mean age for the patients was 36.5 years. The most common comorbidities were lupus nephritis (34.6%), hypothyroidism (18.4%), and anti-phospholipid syndrome (9.2%). The most commonly used medications were hydroxychloroquine (81.8%), corticosteroids (prednisolone) (43.0%), and mycophenolate mofetil (27.9%). Around 45.2% (n= 176) of the patients with SLE developed cardiovascular complications. The most commonly reported cardiovascular diseases that developed after diagnosing patients with SLE were hypertension (22.4%), valvular heart diseases (13.2%), and dyslipidemia (9.2%). The study also found that anti-dsDNA antibodies can reduce the likelihood of developing hypertension by 40%. This research contributes to the medical literature on SLE and sets the stage for future research on personalized healthcare strategies for managing SLE and its complications.CONCLUSIONThis study highlights that a considerable proportion of SLE patients(~50%) develop cardiovascular complications, with hypertension, valvular heart diseases, and dyslipidemia being the most common. We also discovered that anti-double-stranded deoxyribonucleic acid antibodies (Anti-dsDNA) reduce the likelihood of developing hypertension.

2024-04-01·Acta Biomaterialia

pH-responsive size-adjustable liposomes induce apoptosis of fibroblasts and macrophages for rheumatoid arthritis treatment

Article

作者: Liu, Yan ; Tang, Jun ; Nie, Yu ; Mao, Jingying ; Yang, Hong ; Liang, Xiaoya ; Zhang, Zongquan ; Zhou, Xiangyu ; Yang, Xi ; Li, Chunhong ; Wang, Chenglong ; Zheng, Xiu

In rheumatoid arthritis (RA), macrophages infiltrate joints, while fibroblast-like synovial cells proliferate abnormally, forming a barrier against drug delivery, which hinders effective drug delivery to joint focus. Here we firstly designed a pH-responsive size-adjustable nanoparticle, composed by methotrexate (MTX)-human serum albumin (HSA) complex coating with pH-responsive liposome (Lipo/MTX-HSA) for delivering drugs specifically to inflamed joints in acidic environments. We showed in vitro that the nanoparticles can induce mitochondrial dysfunction, promote apoptosis of fibroblast-like synoviocytes and macrophages, further reduce the secretion of inflammatory factors (TNF-α, IL-1β, MMP-9), and regulate the inflammatory microenvironment. We also demonstrated similar effects in a rat model of arthritis, in which Lipo/MTX-HSA accumulated in arthritic joints, and at low pH, liposome phospholipid bilayer cleavage released small-sized MTX-HSA, which effectively reduced the number of fibroblast-synoviocytes and macrophages in joints, alleviated joint inflammation, and repaired bone erosion. These findings suggest that microenvironment-responsive size-adjustable nanoparticles show promise as a treatment against rheumatoid arthritis. STATEMENT OF SIGNIFICANCE: Abnormal proliferation of fibroblast synoviocytes poses a physical barrier to effective nanoparticle delivery. We designed size-adjustable nano-delivery systems by preparing liposomes with cholesterol hemisuccinate (CHEM), which were subsequently loaded with small-sized albumin nanoparticles encapsulating the cytotoxic drug MTX (MTX-HSA), termed Lipo/MTX-HSA. Upon tail vein injection, Lipo/MTX-HSA could be aggregated at the site of inflammation via the ELVIS effect in the inflamed joint microenvironment. Specifically, intracellular acidic pH-triggered dissociation of liposomes promoted the release of MTX-HSA, which was further targeted to fibroblasts or across fibroblasts to macrophages to exert anti-inflammatory effects. The results showed that liposomes with adjustable particle size achieved efficient drug delivery, penetration and retention in joint sites; the strategy exerted significant anti-inflammatory effects in the treatment of rheumatoid arthritis by inducing mitochondrial dysfunction to promote apoptosis in fibrosynoviocytes and macrophages.

2024-03-01·International Forum of Allergy & Rhinology

Hydrocortisone metabolism by Staphylococcus: Effects on anti‐inflammatory and antimicrobial action

Article

作者: Hon, Karen ; Liu, Sha ; Wormald, Peter-John ; Hu, Hua ; Psaltis, Alkis James ; Javadiyan, Shari ; Stafford, Irene ; Cherian, Lisa Mary ; Vreugde, Sarah ; Ramezanpour, Mahnaz

Key Points

Hydrocortisone 21‐hemisuccinate (HCHS) influenced the growth and metabolism of Staphylococcus aureus

S. aureus metabolic activity was high and antibiotic susceptibility low at 1.4 mg/mL HCHS

S. aureus metabolized HCHS to cortisol and reduced poly(I:C)‐induced IL‐6 secretion

100 项与氢化泼尼松琥珀酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01239	氢化泼尼松琥珀酸钠	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	DB14633

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
粘膜皮肤淋巴结综合征	日本	Shionogi Pharma Co., Ltd.	2013-09-13
肾上腺皮质疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
强直性脊柱炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
哮喘	日本	Shionogi Pharma Co., Ltd.	1960-12-24
胶原蛋白疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
脑脊髓炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肉芽肿伴多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
心脏衰竭	日本	Shionogi Pharma Co., Ltd.	1960-12-24
幼年型关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
白血病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
显微镜下多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性硬化症	日本	Shionogi Pharma Co., Ltd.	1960-12-24
重症肌无力	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性肌炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肺纤维化	日本	Shionogi Pharma Co., Ltd.	1960-12-24
风湿热	日本	Shionogi Pharma Co., Ltd.	1960-12-24
类风湿关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
系统性红斑狼疮	日本	Shionogi Pharma Co., Ltd.	1960-12-24
亚急性甲状腺炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MP87-07 (AUA2015)	临床2期	去势抵抗性前列腺癌	120	Intermittent Docetaxel and Prednisolone (DP)	鹽遞齋築憲鹽鹹艱鏇積(網齋鏇範夢夢憲艱齋遞) = 築獵膚觸觸蓋齋廠窪鏇鹹獵壓鏇壓齋積艱糧糧 (蓋鹹鏇蓋觸鹽選醖鏇糧 ) 更多	-	2015-04-01
MRC Myeloma IX (Pubmed \| Blood)	N/A	多发性骨髓瘤	-	Cyclophosphamide, thalidomide, and dexamethasone (CTDa)	(糧鏇鑰鬱鏇蓋觸膚淵鹽) = CTDa was associated with higher rates of constipation 構鏇選壓壓簾積鏇鹽遞 (積鑰觸簾鹹憲範窪繭齋 ) 更多	-	2011-08-04
MRC Myeloma IX (Pubmed \| Blood)	N/A	多发性骨髓瘤	-	Melphalan and prednisolone (MP)		-	2011-08-04
ISRCTN26232583 (Pubmed \| JAMA)	N/A	儿童哮喘	230	Parent initiated prednisolone	艱鏇膚鑰簾顧壓餘衊範(製簾艱鑰廠選鏇觸範簾) = 艱積衊繭選憲齋餘願獵襯憲憲繭鹹鑰顧鑰鬱築 (構窪鏇憲鬱鏇觸夢窪淵 )	积极	2010-03-01